Health News Releases

  • Today April 11
May 16, 2024 14:20
Optiscan Signs Know-How Agreement with Mayo Clinic
Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to develop a digital conf
Carestream CEO Todd Clegg (Photo: Business Wire)
May 16, 2024 13:09
Todd Clegg Named Carestream’s Chief Executive Officer
Carestream, a world-leading provider of medical imaging systems and non-destructive testing solutions, announced that Todd Clegg has been named CEO and appointed to the Board of Directors, effective i
May 16, 2024 10:03
MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead as
May 15, 2024 10:30
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
Takeda (TSE: 4502/NYSE:TAK) (https://www.takeda.com/investors/overview/) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the Am
May 14, 2024 14:10
GRAMINEX®, L.L.C. Final Publication of a Peer Reviewed Clinical Trial with Graminex® Flower Pollen Extract Focusing on Women’s Urinary Incontinence in Current Urology.
Graminex®, L.L.C. is pleased to announce publication of a peer reviewed clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health in Current Urology. The
May 14, 2024 09:55
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53983823&newsitemid=20240510475155&lan=en-US&anchor=Takeda&index=1&md5=4a403ee030780c54b5ebde46e786f5
May 13, 2024 10:20
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Manage
May 10, 2024 14:55
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=53978747&newsitemid=20240508878785&lan=en-US&anchor=BeiGene&index=1&md5=289a1210b11d33d3f6dbd570f8e
May 09, 2024 15:40
LC-Plasma-based Vaccine Research Selected for SCARDA Project
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis str
May 09, 2024 13:55
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML
A groundbreaking research study,[1] sequencing DNA samples from the Pre-MEASURE study[2] strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood
May 07, 2024 14:35
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic derm
May 07, 2024 11:30
Parse Biosciences Launches Single Cell Immune Profiling Products
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR pro
May 03, 2024 10:35
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 bi
WHOOP announces significant global expansion, appoints new senior leadership. Continues “Free Trials
May 01, 2024 12:55
WHOOP Announces Significant Global Expansion, Appoints New Senior Leadership
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2F&esheet=53961244&newsitemid=20240429085870&lan=en-US&anchor=WHOOP&index=1&md5=208ea6634cca605d44e019265ce45daf)
April 28, 2024 13:10
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended
April 28, 2024 11:40
CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads: RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO
April 25, 2024 17:05
Exergen Sues Baxter International to Defend Its Right to Publish Data Regarding the Accuracy of Oral Thermometers
Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts. As detailed in its complaint, Exergen’s lawsuit i
April 25, 2024 14:55
Parse Biosciences Launches Laboratory Automation Provider Program, Collaborates with Hamilton, Opentrons Labworks, SPT Labtech
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation provi
April 24, 2024 14:34
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. · Record net sales of 1.071 billion USD in the first qu
Rubedo Life Sciences scientists (Photo: Business Wire)
April 24, 2024 10:10
Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging
Rubedo Life Sciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.rubedolife.com%2F&esheet=53939040&newsitemid=20240423657886&lan=en-US&anchor=Rubedo+Life+Sciences&index=1&md
April 24, 2024 09:30
ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA tec
April 23, 2024 16:50
AI Medical Service Inc. Signs Joint Research Agreement with Mahidol University in Thailand
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, signed a joint research agreement with Mahidol University in Thailand (herein
High power UV-C LED (Graphic: Business Wire)
April 23, 2024 15:45
Toyoda Gosei Develops UV-C LED with World-Class Light Output
Toyoda Gosei Co., Ltd. (TOKYO:7282) has developed deep ultraviolet (UV-C) LEDs with light output that is among the highest in the world.[1] UV-C is used in disinfection as it destroys viral and bacter
April 23, 2024 09:45
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
Rubedo Life Sciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.rubedolife.com%2F&esheet=53939039&newsitemid=20240422384739&lan=en-US&anchor=Rubedo+Life+Sciences&index=1&md
Learn more about the economic benefits of investing in adult immunisation programmes in a new study
April 18, 2024 15:40
The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
A new report published today reveals that adult vaccination programmes can return up to 19 times their initial investment when the full spectrum of economic and societal benefits is valued. The 19x re
25 per page50 per page75 per page100 per page